Nexbiome Therapeutics is a biotech studio with the mission of translating academic concepts into tangible drugs.

First, Nexbiome identifies innovative concepts through exclusive license agreements or equity participations in existing biotechs. Then it designs, funds, and implements effective strategic roadmaps to create value.

Nexbiome has a team capable of managing drug development projects, offering expertise in non-clinical, preclinical, and clinical areas, from early stages till mature drug development at pharmaceutical standards.

For Nexbiome, any project is eligible, as long as it addresses an unmet medical need in a high-impact area. Nexbiome embodies the next generation of BIO-MEdicines, positively impacting patients’ lives. Founded in 2021 by a single family office with €23 million in equity, Nexbiome initially invested in ten projects. By the end of 2024, the management had selected four of these as the most impactful and promising projects. Nexbiome is now inviting other family offices to join, sharing a long-term vision and a commitment to designing optimal strategies for disseminating innovation and reaching a broader patient population.